 US biotechnology giant Amgen, Inc confirmed weekend speculation that it will be acquiring Horizon Therapeutics by formally unveiling a US26.4bn swoop for the rare diseases drug maker. This will be the most significant transaction in Amgens history and will give the company access to Horizons blockbuster drug, Tepezza, which is used to treat thyroid eye disease. 